Cyclophosphamide and 4-Hydroxycyclophosphamide/Aldophosphamide Kinetics in Patients Receiving High-Dose Cyclophosphamide Chemotherapy

Clinical Cancer Research

Volumn 2, Issue 9, 1996, Pages 1481-1487

  Anderson, Lawrence W ^a   Chen, Tian Ling ^b   Colvin, O Michael ^b   Grochow, Louise B ^b   Collins, Jerry M ^a   Kennedy, M John ^b   Strong, John M ^a,c  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MOD 1 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; 4-HYDROXYCYCLOPHOSPHAMIDE; ALDOPHOSPHAMIDE; ALKYLATING AGENT; CYCLOPHOSPHAMIDE; DRUG DERIVATIVE; PHOSPHORAMIDE MUSTARD; THIOTEPA;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD; BREAST TUMOR; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG INTERACTION; FEMALE; HUMAN; LIVER MICROSOME; METABOLISM; MIDDLE AGED;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; AREA UNDER CURVE; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HUMANS; MICROSOMES, LIVER; MIDDLE AGED; PHOSPHORAMIDE MUSTARDS; THIOTEPA;

EID: 0030223023     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Fried, W., Kedo, A., and Barone, J. Effects of cyclophosphamide and of busulfan on spleen colony-forming units and on hematopoietic stroma. Cancer Res., 37: 1205-1209, 1977.
2. Sensenbrenner, L. L., Manni, J. J., and Colvin, M. Comparative effects of cyclophosphamide, isophosphamide, 4-methylcyclophosphamide, and phosphoramide mustard on murine hematopoietic and immunocompetent cells. J Natl. Cancer Inst., 62: 975-981, 1979.
3. Neidhart, J. A., Kohler, W., Stidley, C., Mangalik, A., Plauche, A , Anderson, T., Quenzer, R. W., and Rinehart, J. J. Phase I study of repeated cycles of high-dose cyclophosphamide, etoposide, and cisplatin administered without bone marrow transplantation J. Clin. Oncol., 8: 1728-1738, 1990
4. Colvin, M., and Hilton, J. Pharmacology of cyclophosphamide and metabolites. Cancer Treat Rep , 65: 89-95, 1982.
5. Sladek, N. E. Metabolism and pharmacokinetic behavior of cyclophosphamide and related oxazaphosphorines In: G. Powis (ed.), Anticancer Drugs: Reactive Metabolism and Drug Interactions, pp. 79-156. Oxford, United Kingdom: Pergamon Press, Ltd., 1994.
6. Chan, K. K, Hong, P. S. Tutsch, K., and Trump, D. L. Clinical pharmacokinetics of cyclophosphamide and metabolites with and without SR-2508. Cancer Res., 54: 6421-6429, 1994.
7. Wagner, T., Heydrich, D., Jork, T., Voelcker, G., and Hohorst, H. J. Comparative study on human pharmacokinetics of activated ifosfamide and cyclophosphamide by a modified fluorometric test. J. Cancer Res. Clin. Oncol., 100: 95-105, 1981.
8. Sladek, N. E., Doeden, D., Powers, J. F., and Krivit, W. Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation. Cancer Treat. Rep., 68: 1247-1254, 1984.
9. Schuler, U., Ehninger, G., and Wagner, T. Repeated high-dose cyclophosphamide administration in bone marrow transplantation: exposure to activated metabolites. Cancer Chemother. Pharmacol., 20: 248-252, 1987.
10. Schuler, U., Waidelich, P., Kolb, H., Wagner T., and Ehninger, G. Pharmacokinetics and metabolism of cyclophosphamide administered after total body irradiation of bone marrow transplant recipients. Eur. J. Clin. Pharmacol., 40: 521-523, 1991.
11. Wright, J. E., Tretyakov, O., Ayash, L. J., Elias, A., and Rosowsky, A. Analysis of 4-hydroxycyclophosphamide in human blood. Anal. Biochem., 224: 154-158, 1995.
12. Struck, R. F., Alberts, D. S., Horne, K., Phillips, J. G., Peng, Y-M., and Roe, D. J. Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, crossover trial. Cancer Res., 47: 2723-2726, 1987.
13. Anderson, L. W., Ludeman, S. M., Colvin, O. M., Grochow, L. B., and Strong, J. M. Quantitation of 4-hydroxycyclophosphamide/aldophosphamide, an activated metabolite of cyclophosphamide. J. Chromatogr. B. Biomed. Appl., 667: 247-257, 1995.
14. Chen, T. L., Passos-Coelho, J. L., Noe, D. A., Kennedy, M. J., Black, K. C., Colvin, O. M., and Grochow, L. B. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Cancer Res., 55: 810-816, 1995.
15. Walsh, S. P., Shulman-Roskes, E. M., Anderson, L. W., Chang, Y. H., and Ludeman, S. M. Synthesis of cyclophosphamide-4,4,5,5.-d4. J. Labelled Compd. Radiopharm., 36: 1193-1198, 1995.
16. Ludeman, S. M., Shulman-Roskes, E. M., Wong, K. K. T., Han, S. Y., Anderson, L. W., Strong, J. M., and Colvin. O. M. Oxime derivatives of the intermediary oncostatic metabolites of cyclophosphamide and ifosfamide: synthesis and deuterium labeling for applications to metabolite quantification. J. Pharm. Sci., 84: 393-398, 1995.
17. Kennedy, M. J., Armstrong, D. K., Huelskamp, A. M., Ohly, K., Clarke, B. V., Colvin, O. M., Grochow, L. B., Chen, T. L., and Davidson, N. E. Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer. J. Clin. Oncol., 13: 1136-1143, 1995.
18. Kennedy, M. J., Vogelsang, G. B., Jones, R. J., Farmer, E. R., Hess, A. D., Altomonte, V., Huelskamp, A. M., and Davidson, N. E. Phase I trial of interferon γ to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J. Clin. Oncol., 12: 249-257, 1994.
19. Lake, B. G. Preparation and characterization of microsomal fractions for studies on xenobiotic metabolism. In: K. Snell and B. Mullock (eds.), Biochemical Toxicology: A Practical Approach, pp. 183-187. Washington, DC: IRL Press, 1987.
20. Chang, T. K. H., Weber, G. F., Crespi, C. L., and Waxman, D. J. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res., 53: 5629-5637, 1993.
21. de Bruijn, E. A., van Oosterom, A. T., Leclercq, P. A., de Haan, J. W., van de Ven, L. J., and Tjaden, U. R. Monitoring the behavior of 4-ketocyclophosphamide versus cyclophosphamide during capillary gas chromatography by mass spectrometry. Biomed. Environ. Mass Spectrom., 14: 643-647, 1987.
22. Jarman, M., Gilby, E. D., Foster, A. R., and Bondy, P. K. The quantitation of cyclophosphamide in human blood and urine by mass spectrometry-stable isotope dilution. Clin Chim. Acta, 58: 61-69, 1975.
23. Gibaldi, M., and Pemer, D. Pharmacokinetics, Ed. 2, pp. 445-449. New York: Marcel Dekker, Inc., 1982.
24. Bagley, C. M., Bostick, F. W., and DeVita, V. T., Jr. Clinical pharmacology of cyclophosphamide. Cancer Res. 33: 226-233, 1973.
25. Graham, M. I., Shaw, I. C., Souhami, R. L., Sidau, B., Harper, P. G., and McLean, A. E. M. Decreased plasma half-life of cyclophosphamide during repeated high-dose administration. Cancer Chemother. Pharmacol., 10: 192-193, 1983.
26. Hong, P. S., Srigritsanapol, A., and Chan, K. K. Pharmacokinetics of 4-hydroxycyclophosphamide and metabolites in the rat. Drug Metab. Dispos.. 19: 1-7, 1991.
27. D'Inacalci, M., Bolis, G., Facchinetti, T., Costantino, M., Morasca, L., Morazzoni, P., and Salmona, M. Decreased half life of cyclophosphamide in patients under continual treatment. Eur. J. Cancer, 15: 7-10, 1979.
28. Sladek, N. E., Priest, J., Doeden, D., Mirocha, C. J., Parthre, S., and Knvit, W. Plasma half-life and urinary excretion of cyclophosphamide in children. Cancer Treat. Rep., 64: 1061-1066, 1980.
29. Motzer, R. J., Gulati, S. C., Tong, W. P., Menendez-Botet, C., Lyn, P., Mazumdar, M., Vlamis, V., Lin, S., and Bosi, G. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors. Cancer Res., 53: 3730-3755, 1993.
30. Ng, S F., and Waxman, D. J. Biotransformation of N,N′,N″-triethylenethiophosphoramide: oxidative desulfuration to yield N,N′N″-triethylenephosphoramide associated with suicide inactivation of a phenobarbital-inducible hepatic P-450 monooxygenase. Cancer Res , 50: 464-471, 1990.